Our leading mass spectrometry technologies are consistently enabling our customers’ important discoveries in medical research, and meeting their growing needs for environmental and consumer safety testing
VANCOUVER, British Columbia--(BUSINESS WIRE)--ASMS 2012 –- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today launched innovative software and instrumentation that extend the capabilities of its flagship mass spectrometry portfolio. The new Thermo Scientific technologies made their debut at the ASMS Conference on Mass Spectrometry and Allied Topics, being held in Vancouver from May 20 - 24.
The analytical power of the company’s highly successful LTQ Orbitrap®hybrid platform is now enhanced by a new suite of software designed to further advance the performance of its recently introduced Elite™ and Q Exactive™ mass spectrometers. Next-generation SIEVE™ 2.0 softwareincreases throughput during complex metabolite and protein biomarker discovery experiments, while new ExactFinder™ 2.0 softwaredramatically improves analysis time in the rapidly changing field of food safety testing. Thermo Fisher also introduced Protein Deconvolution software to fully leverage the high-resolution/accurate mass (HR/AM) data produced by the Q Exactive system during complex protein analysis. These three new offerings are among eight software packages being introduced at ASMS.
For laboratory customers who need to perform quantitative and qualitative analysis, but currently have limited capital budgets, Thermo Fisher launched the new Exactive™ Plus liquid chromatography/mass spectrometry (LC/MS) system. The Exactive Plus system is designed specifically to address the need for high-throughput screening of compounds in a range of applications, including drug metabolism/pharmacokinetics (DMPK), metabolomics, forensic toxicology, environmental analysis and food safety testing. The new Exactive Plus LC/MS can be readily upgraded to match the higher performance of the premier Q Exactive mass spectrometer.
“Our leading mass spectrometry technologies are consistently enabling our customers’ important discoveries in medical research, and meeting their growing needs for environmental and consumer safety testing,” said Marc N. Casper, president and chief executive officer of Thermo Fisher. “Like our customers, we never stop innovating, and these new software launches take our incredibly successful Orbitrap platform to the next level, particularly our Elite and Q Exactive systems. In today’s economic environment, many laboratories are under funding pressure, yet need to deliver results. Our new Exactive Plus gives these customers another option that solves their analytical challenges today, and can be upgraded to full Q Exactive performance in the future.”
Thermo Fisher’s commitment to advancing triple quadrupole technology is evident in its new TSQ 8000™ high-performance gas chromatography-mass spectrometry system (GC-MS/MS), also launched at ASMS. The TSQ 8000 system allows users to view targeted compounds at lower concentrations, making even more complex analyses possible. Compatible with the company’s leading TraceFinder™ 2.1 software, the TSQ 8000 GC-MS/MS is designed for routine applications, including the identification of food and environmental contaminants.
To see the entire Thermo Fisher portfolio of new mass spectrometry instruments, consumables and software, visit the Thermo Scientific hospitality suite in the Parkview Terrace at the Vancouver Convention Center or online at www.thermofisher.com/news.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general worldwide economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; the effect of healthcare reform legislation; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to the acquisitions of Dionex and Phadia may not materialize as expected. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.